Ticker Details
Sangamo Therapeutics, Inc. Sangamo Therapeutics Inc is a clinical stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
IPO Date:	April 6, 2000
Sector:	Healthcare
Industry:	Biotech
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.22 | 3.35%
Avg Daily Range (30 D):	$0.02 | 10.92%
Avg Daily Range (90 D):	$0.02 | 7.62%

Institutional Daily Volume
Avg Daily Volume:	1.45M
Avg Daily Volume (30 D):	13.5M
Avg Daily Volume (90 D):	9.06M

Trade Size
Avg Trade Size (Sh.):	258
Avg Trade Size (Sh.) (30 D):	1,401
Avg Trade Size (Sh.) (90 D):	894

Institutional Trades
Total Institutional Trades:	2,789
Avg Institutional Trade:	$1.5M
Avg Institutional Trade (30 D):	$.64M
Avg Institutional Trade (90 D):	$.64M
Avg Institutional Trade Volume:	.19M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.72M
Avg Closing Trade (30 D):	$.88M
Avg Closing Trade (90 D):	$.88M
Avg Closing Volume:	215.26K

News

Jan 22, 2026 @ 9:56 AM Genome Editing Market Forecast to Reach $23.6 Bill... Source: Researchandmarkets.Com

Mar 18, 2025 @ 10:16 AM US Futures Show Caution Among Investors Ahead Of F... Source: Rishabh Mishra

Feb 21, 2025 @ 6:00 PM Cell and Gene Therapies in Rare Disorders Market t... Source: Delveinsight

Jan 2, 2025 @ 7:30 AM Global Mucopolysaccharidosis Treatment Market to W... Source: Sabyasachi Ghosh (Associate Vice President At Future Market Insights, Inc.)

Dec 31, 2024 @ 2:14 PM Sangamo Therapeutics Stock Plunges As Pfizer Termi... Source: Vandana Singh

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-.38	$-.08	$-.11
Diluted EPS	$-.38	$-.08	$-.11
Revenue	$34.56M	$1.44M	$14.23M
Gross Profit
Net Income / Loss	$-123.33M	$-31M	$-37.42M
Operating Income / Loss	$-123.56M	$-31.95M	$-38.2M
Cost of Revenue
Net Cash Flow	$-14.56M	$6.64M	$-9.58M
PE Ratio